| Literature DB >> 27224444 |
Thomas B Sundberg1, Yanke Liang2,3, Huixian Wu4, Hwan Geun Choi2,3, Nam Doo Kim5, Taebo Sim6, Liv Johannessen2,3, Adam Petrone1, Bernard Khor7, Daniel B Graham8,9, Isabel J Latorre8, Andrew J Phillips1, Stuart L Schreiber4,10,11, Jose Perez1, Alykhan F Shamji4, Nathanael S Gray2,3, Ramnik J Xavier7,8,12.
Abstract
Salt-inducible kinases (SIKs) are promising therapeutic targets for modulating cytokine responses during innate immune activation. The study of SIK inhibition in animal models of disease has been limited by the lack of selective small-molecule probes suitable for modulating SIK function in vivo. We used the pan-SIK inhibitor HG-9-91-01 as a starting point to develop improved analogs, yielding a novel probe 5 (YKL-05-099) that displays increased selectivity for SIKs versus other kinases and enhanced pharmacokinetic properties. Well-tolerated doses of YKL-05-099 achieve free serum concentrations above its IC50 for SIK2 inhibition for >16 h and reduce phosphorylation of a known SIK substrate in vivo. While in vivo active doses of YKL-05-099 recapitulate the effects of SIK inhibition on inflammatory cytokine responses, they did not induce metabolic abnormalities observed in Sik2 knockout mice. These results identify YKL-05-099 as a useful probe to investigate SIK function in vivo and further support the development of SIK inhibitors for treatment of inflammatory disorders.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27224444 PMCID: PMC4992440 DOI: 10.1021/acschembio.6b00217
Source DB: PubMed Journal: ACS Chem Biol ISSN: 1554-8929 Impact factor: 5.100